Veterans Affairs Medical Center - Salt Lake City

Summary

Veterans Affairs Medical Center - Salt Lake City is a medical facility located in undefined, undefined. This center is recognized for care of Lung Cancer, Lymphoma, Leukemia, Breast Cancer, Rectal Cancer and other specialties. Veterans Affairs Medical Center - Salt Lake City is involved with conducting 104 clinical trials across 138 conditions. There are 9 research doctors associated with this hospital, such as Sumati V. Gupta, Tsewang Tashi, Lindsey Fitzgerald, and Shiven Patel.

Top PIs

Clinical Trials running at Veterans Affairs Medical Center - Salt Lake City

Acute Myeloid Leukemia

Prostate Cancer

Kidney Cancer

Cancer

Lung Cancer

Rectal Cancer

Colon Cancer

Myelodysplastic Syndrome

Heart Failure

Chronic Obstructive Pulmonary Disease

Venetoclax + HMA

for Acute Myeloid Leukemia

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.

Recruiting

1 award

Phase 2

7 criteria

Screening Tool

for Myeloid Cancer

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).

Recruiting

0 awards

Phase 2

1 criteria